dwarfism

Graphic image of an arrow nailing the bullseye of a target
Biotech

Ascendis' dwarfism drug hits in phase 3, threatens BioMarin

Ascendis reported phase 3 growth disorder data that exceeded analyst expectations and positions the biotech to file for approval next year.
Nick Paul Taylor Sep 17, 2024 9:36am
pipeline pipes RD research

Sanofi will drop dwarfism drug as part of rare disease clear-out

Jul 25, 2024 7:58am
increase growth

BridgeBio posts BioMarin-beating data on dwarfism drug prospect

Jun 4, 2024 7:30am
orthopedic foot bone

Drug lengthens limb bones in Robinow syndrome

Feb 17, 2023 4:01pm
Unlocked Money

Gene therapy player InnoSkel debuts with €20M

Dec 14, 2020 8:50am
BioMarin

BioMarin nabs FDA review for dwarfism drug vosoritide

Nov 4, 2020 9:52am